Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc.

Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing peptide drug therapies targeting areas of unmet need across rare and prevalent diseases.

msh id	COM:PROTAGONIST-INC
symbol	PTGX
name	Protagonist Therapeutics, Inc.
homepage url	https://www.protagonist-inc.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	124
crunchbase url	-
linkedin url	-
founders	-

market cap	2.04B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.03
growth cost of revenue	2.21
growth depreciation and amortization	-0.02
growth ebitda	0.31
growth ebitda ratio	0.7
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.06
growth gross profit	1.22
growth gross profit ratio	-0.02

COM:PROTAGONIST-INC

Protagonist Therapeutics Inc.

Last Close

40.65

21/11 21:00

Market Cap

2.04B

Beta: -

Volume Today

936.37K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	153.65M
cost of revenue	153.65M
depreciation and amortization	3.31M
ebitda	-90.34M
ebitda ratio	-1.51
eps	-1.39
eps diluted	-1.39
operating expenses	153.65M
operating income	-93.65M
operating income ratio	-1.56

accounts receivables	-9.99M
capital expenditure	-609K
cash at beginning of period	125.97M
cash at end of period	186.95M
inventory	-10.33M
working capital ttm	297.01M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-